Lansdowne Partners

Lansdowne Partners is an alternative investment management firm based in London, England, founded in 1998. The company specializes in managing equity portfolios for a diverse range of institutional clients, including some of the largest and most sophisticated investors globally. Lansdowne Partners operates as a hedge fund company, providing tailored investment strategies primarily through pooled investment vehicles. Its focus on equity allows it to cater to the specific needs of its clientele, emphasizing a commitment to delivering value through careful investment management.

Peter Davies

Partner, Portfolio Manager and Head of Developed Markets Strategy

30 past transactions

Replay

Seed Round in 2022
Replay is a genome writing company focused on advancing genomic medicine by reprogramming biology through the writing and delivery of large DNA sequences. The company has developed a hypoimmunogenic induced pluripotent stem cell (iPSC) therapeutic platform, which aims to enhance the effectiveness of gene therapy and genome editing. By leveraging innovative technologies, Replay seeks to redefine the landscape of genetic treatments and improve patient outcomes in various therapeutic areas.

Oxford Quantum Circuits

Series A in 2022
Oxford Quantum Circuits developing technology using the power of quantum to do things that have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies. OQC's quantum computer is a fully functional unit that includes the control system, hardware, and software. Customers can use OQC's quantum computers to streamline their businesses, pioneer new approaches, and help solve some of humanity's most pressing issues, such as slowing climate change and feeding a rapidly growing population.

AMNIS Treasury Services

Series A in 2022
The powertool to cut international transaction costs, facilitate team spending, and save time on daily accounting tasks. Local CH-IBAN Free, local payments and collections in the UK, US, CH & EU Streamlined expenses with multi-currency debit cards 24/7 currency exchange at transparent rates Interest on safeguarded accounts in EUR, USD, GBP & CZK

OXECO

Venture Round in 2022
OXECO is a chemistry technology firm that creates, engineers, and manufactures specialty chemicals for the clean technology and transportation industries. Using cutting-edge carbene technology, the company's revolutionary ONTOTM technology platform governs how surfaces behave.

MoA Technology

Series B in 2022
MoA Technology Limited is a plant genetics company spun out from the University of Oxford. Professor Liam Dolan, FRS, has developed an innovative approach for the discovery of agricultural technologies that will enable farmers to produce healthy food from sustainable crop systems.

Verve

Series C in 2022
Verve is a global leader in word-of-mouth sales within the live entertainment industry, utilizing networks of advocates to promote events and experiences. By incentivizing these advocates with rewards like free tickets and backstage passes, Verve effectively drives sales for over 500 events across more than 40 countries. The company collaborates with various prominent partners, including major ticketing platforms such as Ticketmaster and Eventbrite, to enhance its offerings. Through its innovative peer-to-peer sales and marketing software, Verve has established itself as a trusted name in the sector, focusing on creating authentic connections within the live entertainment marketplace.

Papier

Series C in 2022
Papier offers customizable stationery such as wedding cards, notebooks, planners, and notecards. Founded in London in 2015, Papier's aim is to inspire people to connect with each other in a more thoughtful way and more often. As digital messages proliferate in their lives, receiving something beautifully made through the letterbox is appreciated now more than ever before - Papier makes this simple and easy to do. At their core, is a love of art and design, words, and of course, paper. Their carefully curated collection of designs, married with quality printing and premium paper, stands us apart from other online card and invitation sites.

Finabro

Seed Round in 2022
FINABRO is your consultant for saving & investing! Proper saving and sensible investing is important for many parts of life. Saving money can be difficult - investing money wisely has become almost impossible. The savings account gives zero interest rates and the different alternative investment forms are risky, intransparent and expensive.

Ribbon Biolabs

Series A in 2022
Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.

Depixus

Series A in 2021
Depixus includes a Full genome analysis, which necessitates technologies capable of reading DNA, RNA, and their base changes. The dynamics of this cannot be captured with single-molecule precision by today's sequencing technology.

Raspberry Pi Foundation

Venture Round in 2021
The Raspberry Pi is a credit-card sized computer that plugs into your TV and a keyboard. It’s a capable little PC which can be used for many of the things that your desktop PC does, like spreadsheets, word-processing and games. It also plays high-definition video.

HELLSICHT

Venture Round in 2021
Hellsicht develops AI technology solutions for the defence and security sector.

TechMet

Venture Round in 2021
TechMet is a private industrial company that is building projects to secure the supply of key metals. TechMet focuses on metals that are essential for various advanced technologies, such as electric vehicles, renewable energy systems, and energy storage devices. The company's primary goal is to ensure a stable and sustainable supply of these critical metals, which are often subject to supply chain challenges due to their importance in emerging technologies. TechMet's investments and projects cover various stages of the metal supply chain, including mining, processing, refining, and recycling. TechMet currently holds interests in both production and development assets in Africa, North America, and South America.

Genomics

Venture Round in 2021
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.

Genomics

Series B in 2018
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.

Genomics

Series B in 2018
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.

Cambridge Innovation Capital

Venture Round in 2016
Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem. Since our inception in 2013, they have raised £275 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.
Drayson Technologies is an Internet of Things platform company using innovative wireless charging technology and machine learning software to create smart sensor networks that deliver tangible business value for customers. They enable energy-efficient and cost-effective IoT data collection and analysis, which reduces the cost of deploying, owning and running IoT networks.

BenevolentAI

Venture Round in 2015
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Spotify

Series G in 2015
Spotify is a commercial music streaming service that provides restricted digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record label, and direct searches. It also enables individuals to create, share, and edit playlists with other users. If users want recommendations, they can integrate their system with Last.fm, an application that provides music recommendations based on listening history. The radio feature installed in Spotify creates random playlists for its users that are related to preferred artists. Spotify is available for mobile device platforms such as Android, Blackberry, Boxee, iOS, Linux, MeeGo, Squeezebox, Windows mobile, and more.

Genomics

Series A in 2014
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.

ACHICA

Series C in 2014
ACHICA is the members-only luxury lifestyle store. ACHICA offers its members up to 70% off luxury home, kitchen, garden children’s, gift, travel and lifestyle brands – all year round. There are new brands every day, each lasting 48 hours and it’s free to join. ACHICA uses the private sale model, which means only its members can access its products and it is closed to search engines and price comparison sites, which in turn protects the brands it promotes. ACHICA is co-founded by online retail experts Quentin Griffiths, formerly one of the co-founders of ASOS and William Cooper former CEO of TradeDoubler, Europe’s largest digital marketing company. Both partners have jointly invested in several online retail ventures since 2000 before launching their first co-owned online retail experience, ACHICA, in February 2010.

Aldermore Bank

Private Equity Round in 2014
Aldermore Bank is a specialist lender and savings bank offering straightforward products to SMEs, homeowners, landlords and individuals.

Displaydata

Venture Round in 2013
Displaydata is the leader in the design and supply of fully graphic Electronic Shelf Labels (ESLs). We were first to market with three-colour ESLs and continue to lead this category, having shipped millions of labels. We work in close partnership with many of the world’s largest retail brands and have operations in the US, Europe, LATAM and Asia. We help retailers optimise revenues and margins by improving the customer experience at the shelf-edge, where most purchasing decisions are made.

Infinity SDC

Venture Round in 2013
Infinity is an award winning UK data centre operator and boasts an impressive portfolio of sites in prime locations close to London. We design, build and maintain highly efficient data centre facilities, helping to minimise our clients’ energy costs and carbon footprints. Our facilities are exceptionally resilient, flexible and secure. Infinity is an award-winning company, and our customer base includes leading investment banks, cloud vendors, systems integrators and telecommunication companies. We always aim to exceed our customers'​ expectations, both commercially and technically. Infinity offers a full range of premium data centre services from 250kW data halls, with shared plant, to fully bespoke, client-dedicated data centres.

Oxford Nanopore Technologies

Venture Round in 2012
Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science, and environmental research. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education. Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data. Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.

Oxford Nanopore Technologies

Venture Round in 2011
Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science, and environmental research. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education. Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data. Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.
Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science, and environmental research. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education. Oxford Nanopore’s proprietary technology is fully scalable for any requirement. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data. The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data. Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.

Circassia

Series C in 2009
Circassia is a dedicated diagnostics and management company focused on asthma. Our market-leading NIOX® products are used by physicians around the world to help improve asthma diagnosis and management, and we support our customers with dedication to outstanding customer service and after sales support. Our purpose is to improve the quality of life for millions of people suffering from asthma. As the leading provider of point-of-care FeNO diagnosis and management products we are making good progress, helping healthcare professionals manage their patients’ asthma. We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.

Circassia

Series B in 2008
Circassia is a dedicated diagnostics and management company focused on asthma. Our market-leading NIOX® products are used by physicians around the world to help improve asthma diagnosis and management, and we support our customers with dedication to outstanding customer service and after sales support. Our purpose is to improve the quality of life for millions of people suffering from asthma. As the leading provider of point-of-care FeNO diagnosis and management products we are making good progress, helping healthcare professionals manage their patients’ asthma. We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.